CAS 1903008-80-9

Lazertinib

CAS : 1903008-80-9

Formule : C₃₀H₃₄N₈O₃

Degré de pureté : 97%

Couleur et forme : Solid

Masse moléculaire : 554.6428

Ref: IN-DA01EB29

N-(5-((4-(4-((Dimethylamino)Methyl)-3-Phenyl-1H-Pyrazol-1-Yl)Pyrimidin-2-Yl)Amino)-4-Methoxy-2-Morpholinophenyl)Acrylamide

CAS : 1903008-80-9

N-(5-((4-(4-((Dimethylamino)Methyl)-3-Phenyl-1H-Pyrazol-1-Yl)Pyrimidin-2-Yl)Amino)-4-Methoxy-2-Morpholinophenyl)Acrylamide

Degré de pureté : 97%

Masse moléculaire : 554.64g/mol

Ref: 54-OR1024173

Lazertinib

CAS : 1903008-80-9

Lazertinib

Degré de pureté : ≥98%

Masse moléculaire : 554.64g/mol

Ref: 54-BUP12851

Lazertinib

CAS : 1903008-80-9

Lazertinib (GNS-1480) is a potent, selective, irreversible EGFR-TKI; IC50: 1.7-76 nM for various EGFR mutations.

Formule : C₃₀H₃₄N₈O₃

Degré de pureté : 98.7% - 99.90%

Couleur et forme : Solid

Masse moléculaire : 554.64

Ref: TM-T4485

Lazertinib

Produit contrôlé

CAS : 1903008-80-9

Formule : C₃₀H₃₄N₈O₃

Couleur et forme : Neat

Masse moléculaire : 554.643

Ref: TR-L215260

Lazertinib

CAS : 1903008-80-9

Lazertinib is a potent tyrosine kinase inhibitor with inhibitory properties against cancer cells. Lazertinib has been shown to have inhibitory effects on epidermal growth factor receptor (EGFR) and HER2/neu receptors, which are important for the growth of solid tumours. This drug inhibits the phosphorylation of these receptors, thereby blocking their downstream signalling pathways that promote cancer cell proliferation. Lazertinib also inhibits the activity of other tyrosine kinases including c-MET, AXL and RET, which may be important for inhibiting cancer cell growth in patients with autoimmune diseases.

Formule : C₃₀H₃₄N₈O₃

Degré de pureté : Min. 95%

Masse moléculaire : 554.64 g/mol

Ref: 3D-DBD00880